nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—ABCC2—Sulfasalazine—Crohn's disease	0.589	1	CbGbCtD
Eprosartan—ABCC2—bile—Crohn's disease	0.0216	0.534	CbGeAlD
Eprosartan—AGTR1—Arf6 trafficking events—VAMP3—Crohn's disease	0.0165	0.186	CbGpPWpGaD
Eprosartan—Rigors—Azathioprine—Crohn's disease	0.00511	0.0181	CcSEcCtD
Eprosartan—Albuminuria—Mesalazine—Crohn's disease	0.00509	0.0181	CcSEcCtD
Eprosartan—AGTR1—epithelium—Crohn's disease	0.00428	0.106	CbGeAlD
Eprosartan—Arthropathy—Mesalazine—Crohn's disease	0.00418	0.0148	CcSEcCtD
Eprosartan—AGTR1—smooth muscle tissue—Crohn's disease	0.00412	0.102	CbGeAlD
Eprosartan—Gout—Mesalazine—Crohn's disease	0.00407	0.0144	CcSEcCtD
Eprosartan—Cystitis noninfective—Mesalazine—Crohn's disease	0.00371	0.0132	CcSEcCtD
Eprosartan—Influenza like illness—Mesalazine—Crohn's disease	0.00369	0.0131	CcSEcCtD
Eprosartan—Cystitis—Mesalazine—Crohn's disease	0.00367	0.013	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—LRRK2—Crohn's disease	0.0036	0.0406	CbGpPWpGaD
Eprosartan—Hypertriglyceridaemia—Prednisone—Crohn's disease	0.0035	0.0124	CcSEcCtD
Eprosartan—Cramps of lower extremities—Mesalazine—Crohn's disease	0.00349	0.0124	CcSEcCtD
Eprosartan—AGTR1—Peptide GPCRs—CCR9—Crohn's disease	0.00347	0.0391	CbGpPWpGaD
Eprosartan—Bladder pain—Mesalazine—Crohn's disease	0.00343	0.0122	CcSEcCtD
Eprosartan—AGTR1—lymphoid tissue—Crohn's disease	0.0033	0.0817	CbGeAlD
Eprosartan—Gastroenteritis—Mesalazine—Crohn's disease	0.00311	0.011	CcSEcCtD
Eprosartan—Eczema—Mesalazine—Crohn's disease	0.00307	0.0109	CcSEcCtD
Eprosartan—Blood triglycerides increased—Prednisone—Crohn's disease	0.00307	0.0109	CcSEcCtD
Eprosartan—Atrial fibrillation—Mesalazine—Crohn's disease	0.00291	0.0103	CcSEcCtD
Eprosartan—Arthritis—Mesalazine—Crohn's disease	0.00284	0.0101	CcSEcCtD
Eprosartan—Osteoarthritis—Mesalazine—Crohn's disease	0.00276	0.00979	CcSEcCtD
Eprosartan—Migraine—Mesalazine—Crohn's disease	0.00271	0.00963	CcSEcCtD
Eprosartan—Neuritis—Prednisone—Crohn's disease	0.00269	0.00955	CcSEcCtD
Eprosartan—Face oedema—Mesalazine—Crohn's disease	0.00266	0.00945	CcSEcCtD
Eprosartan—Arthralgia—Mercaptopurine—Crohn's disease	0.0026	0.00924	CcSEcCtD
Eprosartan—Blood creatinine increased—Mesalazine—Crohn's disease	0.00258	0.00917	CcSEcCtD
Eprosartan—AGTR1—Arf6 trafficking events—ITGA4—Crohn's disease	0.00254	0.0287	CbGpPWpGaD
Eprosartan—Orthostatic hypotension—Mesalazine—Crohn's disease	0.00252	0.00894	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—ACKR2—Crohn's disease	0.00248	0.028	CbGpPWpGaD
Eprosartan—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.00248	0.00881	CcSEcCtD
Eprosartan—Glycosuria—Prednisone—Crohn's disease	0.00248	0.0088	CcSEcCtD
Eprosartan—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00244	0.00868	CcSEcCtD
Eprosartan—Gastritis—Mesalazine—Crohn's disease	0.00244	0.00866	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00243	0.00863	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—MLN—Crohn's disease	0.00238	0.0269	CbGpPWpGaD
Eprosartan—Asthma—Mesalazine—Crohn's disease	0.00238	0.00846	CcSEcCtD
Eprosartan—Anorexia—Mercaptopurine—Crohn's disease	0.00238	0.00845	CcSEcCtD
Eprosartan—ABCC2—digestive system—Crohn's disease	0.00235	0.0583	CbGeAlD
Eprosartan—AGTR1—Peptide ligand-binding receptors—MLN—Crohn's disease	0.00235	0.0266	CbGpPWpGaD
Eprosartan—Angina pectoris—Mesalazine—Crohn's disease	0.00232	0.00824	CcSEcCtD
Eprosartan—AGTR1—Peptide GPCRs—CCR6—Crohn's disease	0.0023	0.0259	CbGpPWpGaD
Eprosartan—Bronchitis—Mesalazine—Crohn's disease	0.00229	0.00813	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.00227	0.00807	CcSEcCtD
Eprosartan—Viral infection—Prednisone—Crohn's disease	0.00222	0.0079	CcSEcCtD
Eprosartan—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.00221	0.00786	CcSEcCtD
Eprosartan—Arthropathy—Prednisone—Crohn's disease	0.00221	0.00784	CcSEcCtD
Eprosartan—Pollakiuria—Mesalazine—Crohn's disease	0.0022	0.00781	CcSEcCtD
Eprosartan—Decreased appetite—Mercaptopurine—Crohn's disease	0.00217	0.0077	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—MLN—Crohn's disease	0.00213	0.0241	CbGpPWpGaD
Eprosartan—Hypercholesterolaemia—Prednisone—Crohn's disease	0.00212	0.00754	CcSEcCtD
Eprosartan—Depression—Mesalazine—Crohn's disease	0.00212	0.00752	CcSEcCtD
Eprosartan—Renal failure—Mesalazine—Crohn's disease	0.00209	0.00741	CcSEcCtD
Eprosartan—Neuropathy peripheral—Mesalazine—Crohn's disease	0.00208	0.00739	CcSEcCtD
Eprosartan—Conjunctivitis—Mesalazine—Crohn's disease	0.00206	0.00733	CcSEcCtD
Eprosartan—Urinary tract infection—Mesalazine—Crohn's disease	0.00206	0.00733	CcSEcCtD
Eprosartan—Haematuria—Mesalazine—Crohn's disease	0.00203	0.00719	CcSEcCtD
Eprosartan—Epistaxis—Mesalazine—Crohn's disease	0.002	0.00711	CcSEcCtD
Eprosartan—Sinusitis—Mesalazine—Crohn's disease	0.00199	0.00707	CcSEcCtD
Eprosartan—Body temperature increased—Mercaptopurine—Crohn's disease	0.00197	0.00701	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—ACKR2—Crohn's disease	0.00194	0.0219	CbGpPWpGaD
Eprosartan—Rhinitis—Mesalazine—Crohn's disease	0.00191	0.00679	CcSEcCtD
Eprosartan—Pharyngitis—Mesalazine—Crohn's disease	0.00189	0.00672	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IL17A—Crohn's disease	0.00189	0.0213	CbGpPWpGaD
Eprosartan—Oedema peripheral—Mesalazine—Crohn's disease	0.00188	0.00667	CcSEcCtD
Eprosartan—Chills—Azathioprine—Crohn's disease	0.00188	0.00667	CcSEcCtD
Eprosartan—AGTR1—lymph node—Crohn's disease	0.00186	0.0461	CbGeAlD
Eprosartan—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00184	0.00653	CcSEcCtD
Eprosartan—Oesophagitis—Prednisone—Crohn's disease	0.00184	0.00652	CcSEcCtD
Eprosartan—Tinnitus—Mesalazine—Crohn's disease	0.00178	0.00631	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IL12B—Crohn's disease	0.00176	0.0198	CbGpPWpGaD
Eprosartan—Chills—Mesalazine—Crohn's disease	0.00171	0.00607	CcSEcCtD
Eprosartan—Diarrhoea—Mercaptopurine—Crohn's disease	0.00171	0.00606	CcSEcCtD
Eprosartan—Ill-defined disorder—Azathioprine—Crohn's disease	0.00169	0.006	CcSEcCtD
Eprosartan—Diabetes mellitus—Prednisone—Crohn's disease	0.00168	0.00595	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ACKR2—Crohn's disease	0.00167	0.0188	CbGpPWpGaD
Eprosartan—Malaise—Azathioprine—Crohn's disease	0.00164	0.00583	CcSEcCtD
Eprosartan—Flatulence—Mesalazine—Crohn's disease	0.00164	0.00581	CcSEcCtD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCR9—Crohn's disease	0.00163	0.0184	CbGpPWpGaD
Eprosartan—Vascular purpura—Prednisone—Crohn's disease	0.00163	0.00579	CcSEcCtD
Eprosartan—Tension—Mesalazine—Crohn's disease	0.00163	0.00578	CcSEcCtD
Eprosartan—Nervousness—Mesalazine—Crohn's disease	0.00161	0.00572	CcSEcCtD
Eprosartan—Back pain—Mesalazine—Crohn's disease	0.00161	0.0057	CcSEcCtD
Eprosartan—Muscle spasms—Mesalazine—Crohn's disease	0.0016	0.00567	CcSEcCtD
Eprosartan—Vomiting—Mercaptopurine—Crohn's disease	0.00159	0.00563	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—MLN—Crohn's disease	0.00158	0.0178	CbGpPWpGaD
Eprosartan—Rash—Mercaptopurine—Crohn's disease	0.00157	0.00559	CcSEcCtD
Eprosartan—Dermatitis—Mercaptopurine—Crohn's disease	0.00157	0.00558	CcSEcCtD
Eprosartan—CYP2C9—digestive system—Crohn's disease	0.00157	0.0388	CbGeAlD
Eprosartan—Tremor—Mesalazine—Crohn's disease	0.00156	0.00552	CcSEcCtD
Eprosartan—Myalgia—Azathioprine—Crohn's disease	0.00155	0.00551	CcSEcCtD
Eprosartan—Arthralgia—Azathioprine—Crohn's disease	0.00155	0.00551	CcSEcCtD
Eprosartan—Ill-defined disorder—Mesalazine—Crohn's disease	0.00154	0.00547	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—GPR65—Crohn's disease	0.00154	0.0173	CbGpPWpGaD
Eprosartan—Discomfort—Azathioprine—Crohn's disease	0.00153	0.00544	CcSEcCtD
Eprosartan—Angioedema—Mesalazine—Crohn's disease	0.00152	0.00538	CcSEcCtD
Eprosartan—Purpura—Prednisone—Crohn's disease	0.00151	0.00537	CcSEcCtD
Eprosartan—Malaise—Mesalazine—Crohn's disease	0.0015	0.00531	CcSEcCtD
Eprosartan—Cardiac failure—Prednisone—Crohn's disease	0.00149	0.00531	CcSEcCtD
Eprosartan—Vertigo—Mesalazine—Crohn's disease	0.00149	0.00529	CcSEcCtD
Eprosartan—Syncope—Mesalazine—Crohn's disease	0.00149	0.00528	CcSEcCtD
Eprosartan—Nausea—Mercaptopurine—Crohn's disease	0.00148	0.00526	CcSEcCtD
Eprosartan—Palpitations—Mesalazine—Crohn's disease	0.00147	0.00521	CcSEcCtD
Eprosartan—Loss of consciousness—Mesalazine—Crohn's disease	0.00146	0.00518	CcSEcCtD
Eprosartan—Osteoarthritis—Prednisone—Crohn's disease	0.00146	0.00518	CcSEcCtD
Eprosartan—Thrombocytopenia—Azathioprine—Crohn's disease	0.00146	0.00517	CcSEcCtD
Eprosartan—Cough—Mesalazine—Crohn's disease	0.00145	0.00514	CcSEcCtD
Eprosartan—Chest pain—Mesalazine—Crohn's disease	0.00141	0.00502	CcSEcCtD
Eprosartan—Myalgia—Mesalazine—Crohn's disease	0.00141	0.00502	CcSEcCtD
Eprosartan—Arthralgia—Mesalazine—Crohn's disease	0.00141	0.00502	CcSEcCtD
Eprosartan—Anxiety—Mesalazine—Crohn's disease	0.00141	0.005	CcSEcCtD
Eprosartan—Face oedema—Prednisone—Crohn's disease	0.00141	0.005	CcSEcCtD
Eprosartan—Discomfort—Mesalazine—Crohn's disease	0.0014	0.00496	CcSEcCtD
Eprosartan—Hypotension—Azathioprine—Crohn's disease	0.00139	0.00493	CcSEcCtD
Eprosartan—Dry mouth—Mesalazine—Crohn's disease	0.00138	0.00491	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—GPR65—Crohn's disease	0.00137	0.0155	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.00136	0.00481	CcSEcCtD
Eprosartan—ABCC2—lymph node—Crohn's disease	0.00134	0.0333	CbGeAlD
Eprosartan—Shock—Mesalazine—Crohn's disease	0.00133	0.00473	CcSEcCtD
Eprosartan—Hypokalaemia—Prednisone—Crohn's disease	0.00133	0.00471	CcSEcCtD
Eprosartan—Thrombocytopenia—Mesalazine—Crohn's disease	0.00133	0.00471	CcSEcCtD
Eprosartan—Tachycardia—Mesalazine—Crohn's disease	0.00132	0.00469	CcSEcCtD
Eprosartan—Hyperhidrosis—Mesalazine—Crohn's disease	0.00131	0.00465	CcSEcCtD
Eprosartan—Anorexia—Mesalazine—Crohn's disease	0.00129	0.00458	CcSEcCtD
Eprosartan—Muscular weakness—Prednisone—Crohn's disease	0.00129	0.00457	CcSEcCtD
Eprosartan—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.00129	0.00457	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IL10—Crohn's disease	0.00129	0.0145	CbGpPWpGaD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR9—Crohn's disease	0.00128	0.0144	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—ACKR2—Crohn's disease	0.00127	0.0143	CbGpPWpGaD
Eprosartan—Hypotension—Mesalazine—Crohn's disease	0.00127	0.00449	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.00123	0.00438	CcSEcCtD
Eprosartan—Sweating increased—Prednisone—Crohn's disease	0.00123	0.00436	CcSEcCtD
Eprosartan—Feeling abnormal—Azathioprine—Crohn's disease	0.00123	0.00435	CcSEcCtD
Eprosartan—Insomnia—Mesalazine—Crohn's disease	0.00123	0.00435	CcSEcCtD
Eprosartan—Paraesthesia—Mesalazine—Crohn's disease	0.00122	0.00432	CcSEcCtD
Eprosartan—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00122	0.00432	CcSEcCtD
Eprosartan—Dyspnoea—Mesalazine—Crohn's disease	0.00121	0.00429	CcSEcCtD
Eprosartan—Somnolence—Mesalazine—Crohn's disease	0.0012	0.00428	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—MLN—Crohn's disease	0.0012	0.0136	CbGpPWpGaD
Eprosartan—Dyspepsia—Mesalazine—Crohn's disease	0.00119	0.00423	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—GPR65—Crohn's disease	0.00119	0.0134	CbGpPWpGaD
Eprosartan—Decreased appetite—Mesalazine—Crohn's disease	0.00118	0.00418	CcSEcCtD
Eprosartan—Abdominal pain—Azathioprine—Crohn's disease	0.00118	0.00417	CcSEcCtD
Eprosartan—Body temperature increased—Azathioprine—Crohn's disease	0.00118	0.00417	CcSEcCtD
Eprosartan—Fatigue—Mesalazine—Crohn's disease	0.00117	0.00415	CcSEcCtD
Eprosartan—Pain—Mesalazine—Crohn's disease	0.00116	0.00411	CcSEcCtD
Eprosartan—Constipation—Mesalazine—Crohn's disease	0.00116	0.00411	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IL2RA—Crohn's disease	0.00115	0.0129	CbGpPWpGaD
Eprosartan—Hyperglycaemia—Prednisone—Crohn's disease	0.00114	0.00404	CcSEcCtD
Eprosartan—Depression—Prednisone—Crohn's disease	0.00112	0.00398	CcSEcCtD
Eprosartan—Feeling abnormal—Mesalazine—Crohn's disease	0.00112	0.00396	CcSEcCtD
Eprosartan—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00111	0.00393	CcSEcCtD
Eprosartan—Neuropathy peripheral—Prednisone—Crohn's disease	0.0011	0.00391	CcSEcCtD
Eprosartan—Hypersensitivity—Azathioprine—Crohn's disease	0.0011	0.00389	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR9—Crohn's disease	0.00109	0.0123	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CCR6—Crohn's disease	0.00108	0.0122	CbGpPWpGaD
Eprosartan—Urticaria—Mesalazine—Crohn's disease	0.00108	0.00382	CcSEcCtD
Eprosartan—Abdominal pain—Mesalazine—Crohn's disease	0.00107	0.0038	CcSEcCtD
Eprosartan—Body temperature increased—Mesalazine—Crohn's disease	0.00107	0.0038	CcSEcCtD
Eprosartan—CYP2C9—Arachidonic acid metabolism—GPX4—Crohn's disease	0.00106	0.012	CbGpPWpGaD
Eprosartan—Bradycardia—Prednisone—Crohn's disease	0.00103	0.00365	CcSEcCtD
Eprosartan—Diarrhoea—Azathioprine—Crohn's disease	0.00102	0.00361	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—GPR65—Crohn's disease	0.00102	0.0115	CbGpPWpGaD
Eprosartan—Hypersensitivity—Mesalazine—Crohn's disease	0.000998	0.00354	CcSEcCtD
Eprosartan—Dizziness—Azathioprine—Crohn's disease	0.000984	0.00349	CcSEcCtD
Eprosartan—Asthenia—Mesalazine—Crohn's disease	0.000972	0.00345	CcSEcCtD
Eprosartan—Pruritus—Mesalazine—Crohn's disease	0.000959	0.0034	CcSEcCtD
Eprosartan—Vomiting—Azathioprine—Crohn's disease	0.000946	0.00336	CcSEcCtD
Eprosartan—Rash—Azathioprine—Crohn's disease	0.000938	0.00333	CcSEcCtD
Eprosartan—Dermatitis—Azathioprine—Crohn's disease	0.000937	0.00333	CcSEcCtD
Eprosartan—Headache—Azathioprine—Crohn's disease	0.000932	0.00331	CcSEcCtD
Eprosartan—Diarrhoea—Mesalazine—Crohn's disease	0.000927	0.00329	CcSEcCtD
Eprosartan—Dizziness—Mesalazine—Crohn's disease	0.000896	0.00318	CcSEcCtD
Eprosartan—Nausea—Azathioprine—Crohn's disease	0.000883	0.00314	CcSEcCtD
Eprosartan—Vomiting—Mesalazine—Crohn's disease	0.000861	0.00306	CcSEcCtD
Eprosartan—Rash—Mesalazine—Crohn's disease	0.000854	0.00303	CcSEcCtD
Eprosartan—Dermatitis—Mesalazine—Crohn's disease	0.000853	0.00303	CcSEcCtD
Eprosartan—Headache—Mesalazine—Crohn's disease	0.000849	0.00301	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR6—Crohn's disease	0.000846	0.00954	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CCR9—Crohn's disease	0.000833	0.0094	CbGpPWpGaD
Eprosartan—Ill-defined disorder—Prednisone—Crohn's disease	0.000815	0.00289	CcSEcCtD
Eprosartan—Nausea—Mesalazine—Crohn's disease	0.000805	0.00286	CcSEcCtD
Eprosartan—Angioedema—Prednisone—Crohn's disease	0.000803	0.00285	CcSEcCtD
Eprosartan—AGTR1—G alpha (q) signalling events—RASGRP1—Crohn's disease	0.000794	0.00896	CbGpPWpGaD
Eprosartan—Malaise—Prednisone—Crohn's disease	0.000792	0.00281	CcSEcCtD
Eprosartan—Vertigo—Prednisone—Crohn's disease	0.000789	0.0028	CcSEcCtD
Eprosartan—Syncope—Prednisone—Crohn's disease	0.000788	0.0028	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—GPR65—Crohn's disease	0.000775	0.00874	CbGpPWpGaD
Eprosartan—Loss of consciousness—Prednisone—Crohn's disease	0.000772	0.00274	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—IFNG—Crohn's disease	0.000756	0.00853	CbGpPWpGaD
Eprosartan—Arthralgia—Prednisone—Crohn's disease	0.000748	0.00265	CcSEcCtD
Eprosartan—Myalgia—Prednisone—Crohn's disease	0.000748	0.00265	CcSEcCtD
Eprosartan—Anxiety—Prednisone—Crohn's disease	0.000745	0.00265	CcSEcCtD
Eprosartan—AGTR1—GPCRs, Class A Rhodopsin-like—PTGER4—Crohn's disease	0.000745	0.0084	CbGpPWpGaD
Eprosartan—Discomfort—Prednisone—Crohn's disease	0.000739	0.00262	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR6—Crohn's disease	0.000725	0.00818	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—Crohn's disease	0.00071	0.00801	CbGpPWpGaD
Eprosartan—Shock—Prednisone—Crohn's disease	0.000705	0.0025	CcSEcCtD
Eprosartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—Crohn's disease	0.000705	0.00796	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—CXCL8—Crohn's disease	0.000703	0.00793	CbGpPWpGaD
Eprosartan—Tachycardia—Prednisone—Crohn's disease	0.0007	0.00248	CcSEcCtD
Eprosartan—Hyperhidrosis—Prednisone—Crohn's disease	0.000693	0.00246	CcSEcCtD
Eprosartan—Anorexia—Prednisone—Crohn's disease	0.000683	0.00243	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—MLN—Crohn's disease	0.000679	0.00766	CbGpPWpGaD
Eprosartan—AGTR1—Allograft Rejection—IL1B—Crohn's disease	0.000674	0.0076	CbGpPWpGaD
Eprosartan—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000653	0.00232	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—ACKR2—Crohn's disease	0.000651	0.00734	CbGpPWpGaD
Eprosartan—Insomnia—Prednisone—Crohn's disease	0.000648	0.0023	CcSEcCtD
Eprosartan—Paraesthesia—Prednisone—Crohn's disease	0.000644	0.00228	CcSEcCtD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	0.000638	0.0072	CbGpPWpGaD
Eprosartan—Dyspepsia—Prednisone—Crohn's disease	0.000631	0.00224	CcSEcCtD
Eprosartan—Decreased appetite—Prednisone—Crohn's disease	0.000623	0.00221	CcSEcCtD
Eprosartan—Fatigue—Prednisone—Crohn's disease	0.000618	0.00219	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—MLN—Crohn's disease	0.000617	0.00696	CbGpPWpGaD
Eprosartan—Constipation—Prednisone—Crohn's disease	0.000613	0.00218	CcSEcCtD
Eprosartan—Feeling abnormal—Prednisone—Crohn's disease	0.000591	0.0021	CcSEcCtD
Eprosartan—Gastrointestinal pain—Prednisone—Crohn's disease	0.000586	0.00208	CcSEcCtD
Eprosartan—Urticaria—Prednisone—Crohn's disease	0.000569	0.00202	CcSEcCtD
Eprosartan—Body temperature increased—Prednisone—Crohn's disease	0.000567	0.00201	CcSEcCtD
Eprosartan—Abdominal pain—Prednisone—Crohn's disease	0.000567	0.00201	CcSEcCtD
Eprosartan—AGTR1—GPCR ligand binding—CCR6—Crohn's disease	0.000552	0.00623	CbGpPWpGaD
Eprosartan—Hypersensitivity—Prednisone—Crohn's disease	0.000528	0.00187	CcSEcCtD
Eprosartan—Asthenia—Prednisone—Crohn's disease	0.000514	0.00183	CcSEcCtD
Eprosartan—Pruritus—Prednisone—Crohn's disease	0.000507	0.0018	CcSEcCtD
Eprosartan—Diarrhoea—Prednisone—Crohn's disease	0.00049	0.00174	CcSEcCtD
Eprosartan—AGTR1—Allograft Rejection—TNF—Crohn's disease	0.000489	0.00552	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—PTGER4—Crohn's disease	0.000486	0.00548	CbGpPWpGaD
Eprosartan—Dizziness—Prednisone—Crohn's disease	0.000474	0.00168	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—CCR9—Crohn's disease	0.000471	0.00531	CbGpPWpGaD
Eprosartan—Vomiting—Prednisone—Crohn's disease	0.000456	0.00162	CcSEcCtD
Eprosartan—Rash—Prednisone—Crohn's disease	0.000452	0.0016	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	0.000452	0.0051	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	0.000452	0.0051	CbGpPWpGaD
Eprosartan—Dermatitis—Prednisone—Crohn's disease	0.000452	0.0016	CcSEcCtD
Eprosartan—Headache—Prednisone—Crohn's disease	0.000449	0.00159	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—GPR65—Crohn's disease	0.000438	0.00494	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCR9—Crohn's disease	0.000428	0.00482	CbGpPWpGaD
Eprosartan—Nausea—Prednisone—Crohn's disease	0.000426	0.00151	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—GPR65—Crohn's disease	0.000397	0.00448	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—GPX4—Crohn's disease	0.000391	0.00441	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ACKR2—Crohn's disease	0.000384	0.00434	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MLN—Crohn's disease	0.000364	0.00411	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—Crohn's disease	0.000362	0.00409	CbGpPWpGaD
Eprosartan—AGTR1—Peptide ligand-binding receptors—CXCL8—Crohn's disease	0.000348	0.00393	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—Crohn's disease	0.000346	0.0039	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TAGAP—Crohn's disease	0.000333	0.00376	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—GCKR—Crohn's disease	0.000318	0.00359	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CCR6—Crohn's disease	0.000312	0.00352	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RSPO3—Crohn's disease	0.000291	0.00329	CbGpPWpGaD
Eprosartan—CYP2C9—Arachidonic acid metabolism—PTGS2—Crohn's disease	0.000286	0.00323	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CCR6—Crohn's disease	0.000283	0.0032	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	0.000281	0.00317	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SEL1L—Crohn's disease	0.000276	0.00312	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PTGER4—Crohn's disease	0.000275	0.0031	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCR9—Crohn's disease	0.000253	0.00285	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PTGER4—Crohn's disease	0.000249	0.00281	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000245	0.00277	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GPR65—Crohn's disease	0.000235	0.00265	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL3—Crohn's disease	0.000234	0.00264	CbGpPWpGaD
Eprosartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	0.000234	0.00264	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—RASGRP1—Crohn's disease	0.000226	0.00255	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL3—Crohn's disease	0.000212	0.0024	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	0.000209	0.00235	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RASGRP1—Crohn's disease	0.000205	0.00232	CbGpPWpGaD
Eprosartan—AGTR1—GPCR ligand binding—CXCL8—Crohn's disease	0.000178	0.00201	CbGpPWpGaD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Crohn's disease	0.000177	0.002	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCR6—Crohn's disease	0.000167	0.00189	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL2RA—Crohn's disease	0.000164	0.00185	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	0.000163	0.00183	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	0.000152	0.00172	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RBX1—Crohn's disease	0.000151	0.00171	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL2RA—Crohn's disease	0.000149	0.00168	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTGER4—Crohn's disease	0.000147	0.00166	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—UBE2D1—Crohn's disease	0.000133	0.0015	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RIPK2—Crohn's disease	0.000129	0.00145	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL3—Crohn's disease	0.000125	0.00142	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RASGRP1—Crohn's disease	0.000121	0.00137	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—JAK2—Crohn's disease	0.00011	0.00124	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SOCS1—Crohn's disease	0.00011	0.00124	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	0.000109	0.00123	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—TYK2—Crohn's disease	0.000105	0.00118	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ALB—Crohn's disease	0.000101	0.00114	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL8—Crohn's disease	0.000101	0.00113	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—JAK2—Crohn's disease	0.0001	0.00113	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SMAD3—Crohn's disease	9.49e-05	0.00107	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTMR3—Crohn's disease	9.29e-05	0.00105	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL8—Crohn's disease	9.13e-05	0.00103	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL2RA—Crohn's disease	8.79e-05	0.000992	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—FADS1—Crohn's disease	7.24e-05	0.000817	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPX4—Crohn's disease	6.78e-05	0.000765	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GCKR—Crohn's disease	6.55e-05	0.000739	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TYK2—Crohn's disease	6.19e-05	0.000699	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JAK2—Crohn's disease	5.91e-05	0.000667	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL8—Crohn's disease	5.39e-05	0.000608	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—Crohn's disease	5.13e-05	0.000578	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	4.68e-05	0.000528	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT3—Crohn's disease	4.34e-05	0.000489	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	4.09e-05	0.000462	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—Crohn's disease	3.03e-05	0.000342	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALB—Crohn's disease	2.08e-05	0.000235	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—Crohn's disease	1.82e-05	0.000206	CbGpPWpGaD
